- 34 Downloads
Interleukins and tumour necrosis factor (TNF) are a complex group of proteins and glycoproteins able to exert pleiotropic effects with respect to a number of different target cells. In physiological conditions, they are induced and released in basal amounts only in restricted micro-environments where they have paracrine activity. Any small amounts reaching the circulation do not disturb homoeostasis. During therapy, particularly when these cytokines are administered via conventional routes, it has become apparent that their presence in nonphysiological plasma concentrations and their unselective action cause toxic effects with small benefits.
The pharmacokinetics of interleukins-1, -2, -3 and -6 and TNF have been evaluated, and their disappearance from plasma after intravenous administration is very rapid (i.e. the distribution half-life is measured in minutes; the elimination half-life is several hours). The efficiency of catabolic pathways such as renal filtration and/or liver uptake is interpreted as a salutary mechanism for extracting proteins that should not be in the circulation. However, because these cytokines are very potent immunomodulatory agents there is a need to improve their therapeutic index, and to this end a number of possible formulations and routes of administration are now available and may eventually be of practical use.
KeywordsInterferon Biological Response Modifier Capillary Leak Syndrome Recombinant Human Tumor Necrosis Factor Yale Journal
Unable to display preview. Download preview PDF.
- Asher A, Mulé JJ, Reichert C, Shiloni E, Rosenberg SA. Studies on the anti-tumor efficacy of systematically administered recombinant tumor necrosis factor against several murine tumors in vivo. Journal of Immunology 138: 963–974, 1987Google Scholar
- Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. Journal of Immunology 135: 3972–3977, 1985Google Scholar
- Bocci V. Distribution, catabolism and pharmacokinetics of interferons. In Finter & Oldham (Eds) Interferon: in vivo and clinical studies, Vol. 4, pp. 47–72, Elsevier Science Publishers BV, Amsterdam, 1985cGoogle Scholar
- Bocci V. Central nervous system toxicity of interferons and other cytokines. Journal of Biological Regulators and Homeostatic Agents 3: 107–118, 1988bGoogle Scholar
- Bocci V. What roles have anti-interferon antibodies in physiology and pathology? Research in Clinic and Laboratory, in press, 1991aGoogle Scholar
- Bocci V, Satoh Y, Pacini A, Pessina GP, Paulesu L, et al. Metabolic behaviour of recombinant interferons β. IRCS Medical Science Research 15: 187–188, 1987bGoogle Scholar
- Castell JV, Andus T, Kunz D, Heinrich PC. The major regulator of acute-phase protein synthesis in man and rat. In Sehgal et al. (Eds) Annals of the New York Academy of Sciences: regulation of the acute phase and immune responses — interlukin-6, Vol. 557, pp. 87–99, New York Academy of Sciences, New York, 1989Google Scholar
- Cheever MA, Thompson JA, Kern DE, Greenberg PD. Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. Journal of Immunology 134: 3895–3900, 1985Google Scholar
- Donohue JH, Rosenberg SA. The fate of interleukin-2 after in vivo administration. Journal of Immunology 130: 2203–2208, 1983Google Scholar
- Garland JM, Aldridge A, Wagstaffe J, Dexter TM. Studies on the in vivo production of a lymphokine activity, interleukin 3 (IL-3) elaborated by lymphocytes and a myeloid leukaemic line in vitro and the fate of IL-3 dependent cell lines. British Journal of Cancer 48: 247–259, 1983PubMedCrossRefGoogle Scholar
- Katre NV. Immunogenicity of recombinant IL-2 modified by covalent attachment of polyethylene glycol. Journal of Immunology 144: 209–213, 1990Google Scholar
- Kimball ES, Pickerai SF, Oppenheim JJ, Rossio JL. Interleukin 1 activitiy in normal human urine. Journal of Immunologyu 133: 256–260, 1984Google Scholar
- Lotze MT, Matory YL, Ettinghausen SE, Rayner AA, Sharrow SO, et al. In vivo administration of purified human interleukin 2: II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. Journal of Immunology 135: 2865–2875, 1985Google Scholar
- Matsuda T, Hirano T, Nagasawa S, Kishimoto T. Identification of α2-macroglobulin as a carrier protein for IL-6. Journal of Immunology 142: 148–152, 1989Google Scholar
- Seckinger P, Zhang JH, Haputmann B, Dayer JM. Characterization of a tumor necrosis factor α (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proceedings of the National Academy of Sciences of the United States of America 87: 5188–5192, 1990PubMedCrossRefGoogle Scholar
- Siegel JP, Lane HC, Stocks NI, Quinnan Jr GV, Fauci AS. Pharmacokinetics of lymphocyte-derived and recombinant DNA-derived interleukin-2 after intravenous administration to patients with the acquired immunodeficiency syndrome. Journal of Biological Response Modifiers 4: 596–601, 1985PubMedGoogle Scholar